Anthem Biosciences Ltd Q2 FY26 Earnings Analysis

- Anthem Biosciences expects steady growth with a historical CAGR of around 20% year-on-year, maintaining this outlook for FY25 vs FY26 and beyond. - Growth is driven largely by commercialized molecules, with multiple products seeing increased demand across several clients. - There is significant headroom for growth across existing commercial products, but sales volumes may not increase every quarter due to customer stocking patterns. - The company plans capacity expansions ahead of demand to support future growth, anticipating customers’ needs and new modalities. - Development-stage products and new modalities like peptides and ADCs will contribute to growth over multiple years, though with longer gestation and smaller volumes initially. - Growth in CRO (Contract Research Organization) segment is expected to be driven by adding scientific talent and expanding lab capacities. - Customer expansion includes both innovators and emerging biotech, with no significant pricing pressure currently anticipated.

- Anthem Biosciences targets steady margins in EBITDA, gross margin, and PAT margin levels, maintaining around 38% EBITDA margin as seen in FY25. - The company anticipates about 20% CAGR growth in revenues year-on-year for FY26 and beyond, consistent with its historical performance. - Growth drivers include increased demand for commercial products and capacity expansions in custom synthesis and fermentation. - Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. - New product segments like GLP-1 peptides are expected to be exciting growth drivers over the next 2-3 years. - Management is cautiously optimistic, preferring to wait on upcoming quarters before updating outlook but remains confident in medium-term growth. - EBITDA and gross margins expected to remain steady without significant fluctuations.

- Anthem Biosciences is undertaking capacity expansion with a capital commitment of about INR 150 crores to complete Unit 2 and Unit 3 commissioning. - Unit 4 expansion is in early planning stage; detailed plans and capex numbers will be shared once finalized. - Expansion funding will primarily come from internal accruals and existing net cash balance of about INR 785 crores. - The company has recently commissioned 54 kiloliters of custom synthesis capacity in Q1 FY26; balance 76 kiloliters to be added by end of calendar year. - Additional 25 kiloliters peptide synthesis capacity built in NeoAnthem unit as part of custom synthesis expansion. - An additional 40 kiloliters of fermentation capacity is being added at NeoAnthem, expected to complete in calendar year. - Anthem follows a strategy of investing ahead of demand to avoid capacity shortages and seize growth opportunities.

- Anthem Biosciences currently holds about INR 785 crores of net cash. - The company plans to deploy a large portion of this cash towards capacity expansion (units 2, 3, and 4). - Unit 4 is in early planning stages, and detailed capital expenditure plans will be shared once finalized. - Management indicated that if attractive borrowing rates are available, they would consider taking on debt. - However, the company aims to maintain a positive net cash position and prefers funding expansions primarily through internal accruals/net cash. - No specific announcements of new fundraising through debt or equity have been made as of now.

- Anthem Biosciences has multiple ongoing projects with clients, both in development and commercialization stages, indicating a robust order book. - The company works with global pharmaceutical companies and handles several late-stage Phase 3 molecules, some moving to commercialization. - They have around 10 molecules in Phase 3 as of March 2025, with 2 recently approved and commercialized, indicating active project pipeline. - Anthem is also involved in lateral projects and becoming a second source for existing products, adding to their pending order prospects. - Capacity expansions (units 2, 3, and upcoming unit 4) are aligned with the expected growth in order volumes. - Management has emphasized multi-year, multi-product engagements with clients, suggesting committed order flow over coming years. - The company expects continued demand from established commercial molecules and projects under development to steadily contribute to revenues.